Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy’s First-To-File ANDAs At Risk In FDA Data Integrity Probe

This article was originally published in PharmAsia News

Executive Summary

Several first-to-file ANDAs are on the line for Ranbaxy as it tries to resolve data integrity issues at its Paonta Sahib facility with U.S. FDA

You may also be interested in...



"We Know We Will Emerge Stronger In The U.S.," Says Ranbaxy CEO Atul Sobti: An Interview With PharmAsia News (Part 2 of 2)

Now under majority ownership by Daiichi Sankyo the Indian drug maker is revisiting its U.S. business model, with "very innovative" plans for generics, OTC and branded drugs, Sobti says.

"We Know We Will Emerge Stronger In The U.S.," Says Ranbaxy CEO Atul Sobti: An Interview With PharmAsia News (Part 2 of 2)

Now under majority ownership by Daiichi Sankyo the Indian drug maker is revisiting its U.S. business model, with "very innovative" plans for generics, OTC and branded drugs, Sobti says.

"We Know We Will Emerge Stronger In The U.S.," Says Ranbaxy CEO Atul Sobti: An Interview With PharmAsia News (Part 2 of 2)

Japan's third-largest drug maker, Daiichi Sankyo, acquired a 64- percent stake in India's most internationally known pharmaceutical brand - Ranbaxy - last June. The deal between an emerging innovator and an established generics drug maker surprised many, but was seen as a transformational one with a goal to expand reach and enhance cost efficiencies. Daiichi Sankyo was criticized later as concerns surfaced regarding Ranbaxy's manufacturing standards at two of its U.S.FDA-approved sites in India. After a complete management overhaul that saw Ranbaxy's promoter exiting the company, Daiichi Sankyo made Atul Sobti the CEO and managing director. In arguably the most in-depth interview after taking over the reins of Ranbaxy, Sobti, who has worked previously with companies like Hero Honda, opened up to PharmAsia News' India bureau on issues spanning U.S. FDA's actions to rebuilding Ranbaxy's reputation and opportunities in Europe, Africa, Japan and India.

Related Content

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel